Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Exp Neurol ; 219(2): 481-91, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19576888

RESUMEN

The neuroprotective effects and mechanism of action of GIF-0173, a Delta12-prostaglandin J analogue, were investigated in the early phase of cerebral ischemia. GIF-0173 was administered intravenously immediately following middle cerebral artery occlusion (MCAO) in photochemically induced thrombosis model of rat. Neurological scores and infarct sizes were examined at 24 h after MCAO. Cerebral blood flow (CBF) was monitored by laser-Doppler flowmetry for 1 h after MCAO. In cultured cortical neurons obtained from 1-day-old rats, the effects of GIF-0173 on the excitotoxicity induced by glutamate were examined. Morphological changes, neuronal death, and changes in intracellular calcium concentration ([Ca(2+)](i)) were also examined. GIF-0173 improved neurological scores and reduced the infarct size in a dose-dependent manner following MCAO. But GIF-0173 did not improve CBF after MCAO. GIF-0173 also prevented glutamate-induced neuronal death and acute cellular swelling in primary cultures in a dose-dependent manner, indicating that it inhibited neuronal necrosis. GIF-0173 dose-dependently suppressed the glutamate-induced increase in [Ca(2+)](i), but could not inhibit NMDA-induced calcium influx. The effects of GIF-0173 against glutamate-induced [Ca(2+)](i) increase were reversed by addition of non-specific prostaglandin D (PGD(2)) receptor antagonist and were comparable to the effects of PGD(2) DP1 receptor agonist, which prevented [Ca(2+)](i) increase and neuronal death. We conclude that GIF-0173 reduces cerebral infarction and protects cultured neurons against glutamate-induced excitotoxicity by inhibiting [Ca(2+)](i) increase through DP1 receptor activation.


Asunto(s)
Infarto Encefálico/prevención & control , Dantroleno/uso terapéutico , Fármacos Neuroprotectores/uso terapéutico , Receptores Inmunológicos/metabolismo , Receptores de Prostaglandina/metabolismo , Animales , Infarto Encefálico/etiología , Calcio/metabolismo , Muerte Celular/efectos de los fármacos , Células Cultivadas , Corteza Cerebral , Circulación Cerebrovascular/efectos de los fármacos , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Ácido Glutámico/toxicidad , Hidantoínas/farmacología , Infarto de la Arteria Cerebral Media/inducido químicamente , Infarto de la Arteria Cerebral Media/complicaciones , Líquido Intracelular/efectos de los fármacos , Líquido Intracelular/metabolismo , Lactonas/farmacología , Flujometría por Láser-Doppler/métodos , Masculino , N-Metilaspartato/toxicidad , Neuronas/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/farmacología , Prostaglandina D2/análogos & derivados , Prostaglandina D2/uso terapéutico , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Sesquiterpenos/farmacología , Índice de Severidad de la Enfermedad , Sales de Tetrazolio
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA